MX2020003381A - Composicion para la prevencion o el tratamiento de enfermedades relacionadas con el factor de necrosis tumoral (tnf), que contiene un nuevo derivado como ingrediente activo, y metodo para inhibir la actividad del factor de necrosis tumoral (tnf) mediante el uso de la misma. - Google Patents
Composicion para la prevencion o el tratamiento de enfermedades relacionadas con el factor de necrosis tumoral (tnf), que contiene un nuevo derivado como ingrediente activo, y metodo para inhibir la actividad del factor de necrosis tumoral (tnf) mediante el uso de la misma.Info
- Publication number
- MX2020003381A MX2020003381A MX2020003381A MX2020003381A MX2020003381A MX 2020003381 A MX2020003381 A MX 2020003381A MX 2020003381 A MX2020003381 A MX 2020003381A MX 2020003381 A MX2020003381 A MX 2020003381A MX 2020003381 A MX2020003381 A MX 2020003381A
- Authority
- MX
- Mexico
- Prior art keywords
- tnf
- related diseases
- same
- composition
- preventing
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- 201000010099 disease Diseases 0.000 title abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
- 230000000694 effects Effects 0.000 title abstract 3
- 230000002401 inhibitory effect Effects 0.000 title abstract 3
- 238000000034 method Methods 0.000 title abstract 3
- 239000004480 active ingredient Substances 0.000 title abstract 2
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- OTAFHZMPRISVEM-UHFFFAOYSA-N chromone Chemical class C1=CC=C2C(=O)C=COC2=C1 OTAFHZMPRISVEM-UHFFFAOYSA-N 0.000 abstract 1
- 230000001900 immune effect Effects 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
- C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
- C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
- C07D311/30—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only not hydrogenated in the hetero ring, e.g. flavones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/324—Foods, ingredients or supplements having a functional effect on health having an effect on the immune system
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrane Compounds (AREA)
Abstract
La presente invención se refiere a: un derivado de la 4-benzopiranona y una sal, un disolvente, un racemato o un estereoisómero de la misma aceptable desde el punto de vista farmacéutico; una composición para prevenir, aliviar o tratar las enfermedades relacionadas con el TNF, que contiene lo mismo que un ingrediente activo; y un método para tratar las enfermedades relacionadas con el TNF, una composición reactiva para inhibir el TNF y un método para inhibir el TNF, todos los cuales usan lo mismo. Las composiciones pueden administrarse por vía oral para no causar efectos secundarios en las inyecciones, no causan tolerancia inmunológica y pueden inhibir eficazmente la actividad del TNF al estar ligadas directamente al TNF, facilitando al mismo tiempo la administración conjunta con una preparación oral convencional y el control de la dosis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170135899A KR101934651B1 (ko) | 2017-10-19 | 2017-10-19 | 신규한 유도체를 유효성분으로 포함하는 tnf-관련 질환 예방 또는 치료용 조성물 및 이를 이용한 tnf 활성 억제 방법 |
PCT/KR2018/007922 WO2019078452A1 (ko) | 2017-10-19 | 2018-07-12 | 신규한 유도체를 유효성분으로 포함하는 tnf-관련 질환 예방 또는 치료용 조성물 및 이를 이용한 tnf 활성 억제 방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020003381A true MX2020003381A (es) | 2020-08-03 |
Family
ID=65021450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020003381A MX2020003381A (es) | 2017-10-19 | 2018-07-12 | Composicion para la prevencion o el tratamiento de enfermedades relacionadas con el factor de necrosis tumoral (tnf), que contiene un nuevo derivado como ingrediente activo, y metodo para inhibir la actividad del factor de necrosis tumoral (tnf) mediante el uso de la misma. |
Country Status (11)
Country | Link |
---|---|
US (2) | US11504349B2 (es) |
EP (1) | EP3699174A4 (es) |
JP (2) | JP2020536977A (es) |
KR (1) | KR101934651B1 (es) |
CN (1) | CN111315730A (es) |
AU (1) | AU2018353722C1 (es) |
BR (1) | BR112020007826A2 (es) |
CA (1) | CA3074993C (es) |
MX (1) | MX2020003381A (es) |
WO (1) | WO2019078452A1 (es) |
ZA (1) | ZA202001887B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101934651B1 (ko) * | 2017-10-19 | 2019-01-02 | 가톨릭대학교 산학협력단 | 신규한 유도체를 유효성분으로 포함하는 tnf-관련 질환 예방 또는 치료용 조성물 및 이를 이용한 tnf 활성 억제 방법 |
KR102379145B1 (ko) * | 2019-07-25 | 2022-03-28 | 서울대학교 산학협력단 | PICALM 저해제 및 mTORC1 저해제를 포함하는 당뇨병 매개 신경퇴행성질환의 예방, 개선 또는 치료용 조성물 |
KR20210026308A (ko) * | 2019-08-29 | 2021-03-10 | (주)아이랩 | 벤조피라논 화합물의 염 및 결정형, 이의 제조 방법, 및 이를 포함하는 약학적 조성물 |
KR20210036162A (ko) | 2019-09-25 | 2021-04-02 | (주)아이랩 | 벤조피라논 화합물의 결정형, 이의 제조 방법, 및 이를 포함하는 약학적 조성물 |
KR102105483B1 (ko) * | 2019-10-23 | 2020-04-28 | 가톨릭대학교 산학협력단 | 테트라하이드로파파베린 및 il-6 억제제를 유효성분으로 포함하는 tnf-관련 질환 예방 또는 치료용 조성물 및 이를 이용한 tnf 활성 억제 방법 |
CN110898052A (zh) * | 2019-12-21 | 2020-03-24 | 贵州中医药大学 | 山萘酚在制备治疗脓毒症药物中的应用 |
KR102379963B1 (ko) | 2020-04-20 | 2022-03-29 | (주)아이랩 | 벤조피라논 화합물의 제조 방법 및 이에 사용되는 신규한 중간체 |
KR20220005991A (ko) | 2020-07-07 | 2022-01-14 | (주)아이랩 | 신규한 tnf 활성 억제제 화합물 및 이의 약학적으로 허용가능한 염 |
WO2022140667A2 (en) * | 2020-12-23 | 2022-06-30 | Icahn School Of Medicine At Mount Sinai | Method for treating crohn's disease |
CN112939917B (zh) * | 2021-02-08 | 2023-08-22 | 中山大学 | 一种黄酮类化合物的制备方法 |
CN113214351B (zh) * | 2021-04-09 | 2021-11-30 | 华南师范大学 | 胡芦巴蛋白及其分离提取方法和在制备骨髓hsc清除辅助剂中的应用 |
EP4112051A1 (en) * | 2021-06-30 | 2023-01-04 | Op2 Drugs | Anethole trithione for the treatment of vasculitides |
CN114788875B (zh) * | 2022-05-25 | 2023-05-30 | 中国医学科学院放射医学研究所 | 一种激活Hippo通路的超分子纳米药物及其制备方法与应用 |
CN116370452A (zh) * | 2022-12-15 | 2023-07-04 | 山东大学 | 萝卜硫素在缓解糖尿病性心肌病中的应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3715779A1 (de) | 1987-05-12 | 1988-11-24 | Kali Chemie Pharma Gmbh | Flavon-3-carbonsaeure-verbindungen sowie verfahren, zwischenprodukte zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
WO2001072735A2 (en) * | 2000-03-28 | 2001-10-04 | Chugai Seiyaku Kabushiki Kaisha | Benzopyranes useful as tnf alpha inhibitors |
AU2001294996A1 (en) * | 2000-07-31 | 2002-02-13 | University Of Maryland, Baltimore | Immunomodulatory compounds |
CA2417635C (en) * | 2000-08-11 | 2008-02-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
KR20080013162A (ko) * | 2006-08-07 | 2008-02-13 | 한국과학기술연구원 | 용액상 평행 조합화학을 이용한 크로몬-3-카복실산유도체의 제조방법 |
EP2112145A1 (en) * | 2008-04-24 | 2009-10-28 | AxoGlia Therapeutics S.A. | Chromenone derivatives useful for the treatment of neurodegenerative diseases |
KR101263356B1 (ko) | 2011-02-23 | 2013-05-16 | 정종문 | 항염증용 식품 조성물 |
KR101640284B1 (ko) | 2013-05-09 | 2016-07-15 | 가톨릭대학교 산학협력단 | 메트포민과 퀘르세틴을 유효성분으로 함유하는 면역 질환의 예방 또는 치료용 조성물 |
KR20160101732A (ko) | 2015-02-17 | 2016-08-26 | 유한회사한풍제약 | 포도잎 추출물 또는 이로부터 분리한 퀘르세틴-3-o-글루쿠로니드를 유효성분으로 함유하는 뇌질환의 예방, 개선 또는 치료를 위한 조성물 |
KR101746286B1 (ko) | 2015-10-13 | 2017-06-12 | 가톨릭대학교 산학협력단 | 케르세틴-3-o-자이로사이드를 유효성분으로 포함하는 면역 증강용 조성물 |
KR101934651B1 (ko) * | 2017-10-19 | 2019-01-02 | 가톨릭대학교 산학협력단 | 신규한 유도체를 유효성분으로 포함하는 tnf-관련 질환 예방 또는 치료용 조성물 및 이를 이용한 tnf 활성 억제 방법 |
-
2017
- 2017-10-19 KR KR1020170135899A patent/KR101934651B1/ko active IP Right Grant
-
2018
- 2018-07-12 EP EP18869374.1A patent/EP3699174A4/en active Pending
- 2018-07-12 AU AU2018353722A patent/AU2018353722C1/en active Active
- 2018-07-12 WO PCT/KR2018/007922 patent/WO2019078452A1/ko unknown
- 2018-07-12 CA CA3074993A patent/CA3074993C/en active Active
- 2018-07-12 BR BR112020007826-3A patent/BR112020007826A2/pt active Search and Examination
- 2018-07-12 MX MX2020003381A patent/MX2020003381A/es unknown
- 2018-07-12 JP JP2020542224A patent/JP2020536977A/ja not_active Withdrawn
- 2018-07-12 US US16/757,112 patent/US11504349B2/en active Active
- 2018-07-12 CN CN201880067639.8A patent/CN111315730A/zh active Pending
-
2020
- 2020-03-24 ZA ZA2020/01887A patent/ZA202001887B/en unknown
-
2022
- 2022-04-15 JP JP2022067394A patent/JP2022092052A/ja active Pending
- 2022-10-06 US US17/961,472 patent/US11850230B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3699174A1 (en) | 2020-08-26 |
NZ763267A (en) | 2023-08-25 |
JP2020536977A (ja) | 2020-12-17 |
CN111315730A (zh) | 2020-06-19 |
RU2020114870A (ru) | 2021-11-19 |
US11504349B2 (en) | 2022-11-22 |
BR112020007826A2 (pt) | 2020-10-20 |
ZA202001887B (en) | 2021-06-30 |
US20230099574A1 (en) | 2023-03-30 |
RU2020114870A3 (es) | 2021-11-19 |
AU2018353722C1 (en) | 2022-10-27 |
US11850230B2 (en) | 2023-12-26 |
JP2022092052A (ja) | 2022-06-21 |
CA3074993C (en) | 2022-08-16 |
EP3699174A4 (en) | 2021-11-10 |
AU2018353722B2 (en) | 2021-07-29 |
CA3074993A1 (en) | 2019-04-25 |
KR101934651B1 (ko) | 2019-01-02 |
WO2019078452A1 (ko) | 2019-04-25 |
AU2018353722A1 (en) | 2020-04-23 |
US20200246304A1 (en) | 2020-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020003381A (es) | Composicion para la prevencion o el tratamiento de enfermedades relacionadas con el factor de necrosis tumoral (tnf), que contiene un nuevo derivado como ingrediente activo, y metodo para inhibir la actividad del factor de necrosis tumoral (tnf) mediante el uso de la misma. | |
MX2017010477A (es) | Compuestos triciclicos y usos de los mismos en medicina. | |
MX2021011563A (es) | Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen. | |
WO2013158680A3 (en) | Compositions and methods comprising celecoxib or related compounds and dextromethorphan | |
EA201690102A1 (ru) | Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе | |
MX2013012588A (es) | Inhibidores de cinasa. | |
SA517381749B1 (ar) | صيغ من 2-(تيرت-بيوتيل أمينو)-4-((1r،3r،4r)-3-هيدروكسي-4-ميثيل سيكلو هكسيل أمينو)-بيريميدين-5-كربوكساميد | |
MX2020008173A (es) | Combinacion de un agente antimuscarinico o de uno anticolinergico y acido lipoico, y sus usos. | |
EP4275677A3 (en) | Dosage regimen for a controlled-release pth compound | |
NZ587202A (en) | Methods for measuring a patient response upon administration of a drug and compositions thereof | |
MX2021009868A (es) | Nuevo derivado de pirido[3,4-d]pirimidin-8-ona que tiene actividad inhibidora de proteína cinasa y composición farmaceutica para prevenir, aliviar o tratar el cáncer, que comprende el mismo. | |
AU2018282104A1 (en) | Use of vibegron to treat overactive bladder | |
MX2018000084A (es) | Una composicion farmaceutica que comprende amlodipino, valsartan y rosuvastatina. | |
MX2021010046A (es) | Nueva composicion terapeutica que contiene ingrediente activo de apomorfinas. | |
BR112013021566A2 (pt) | composto de fórmula, ou um aduto ou sal farmaceuticamente aceitável do mesmo e método de prevenção e/ou tratamento de um indivíduo que compreende a administração ao dito indivíduo uma quantidade terapeuticamente eficaz de um composto de fórmula | |
MX2017003780A (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
JOP20210185A1 (ar) | مركبات هالو-آلِّيلامين واستخدامها | |
PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
MX2015017879A (es) | Derivados de estratrientiazol 17-nitrogeno substitutidos terapeuticamente activos como inhibidores de 17.beta-hidroxiestero ide deshidrogenasa. | |
MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
MY193963A (en) | Composition for treating joint diseases and kit containing same | |
TW201613606A (en) | Therapeutic drug for chronic renal failure | |
WO2014007549A3 (ko) | 에스-알릴-엘-시스테인을 유효성분으로 포함하는 대장염 예방 또는 치료용 조성물 및 이를 포함하는 의약제제 | |
MX2017013481A (es) | Composicion farmaceutica de liberacion sostenida que contiene rivastigmina. | |
RU2013126798A (ru) | Комбинированная терапия дексаметазоном |